Skip to main content
RVPH logo

RVPH · Reviva Pharmaceuticals Holdings, Inc.

Track RVPH — free
$0.39 +0.04 (+10.76%) At close · May 14
Market Cap
$6.33M
Shares
13.11M
Volume · May 14 742.02K Avg daily vol (48 sessions) 985.8K

Price & Indicators

 

Key stats

Close
$0.39
Thu 14 May
Open
$0.36
Thu 14 May
Average volume, 30 days
925K
shares a session
Short interest
409K
3.1% of shares · 3.4 days to cover
Day range
$0.31$0.39
Open $0.36 Close $0.39
52-week closing range
$0.35$22.40
Close $0.39 98.3% under the high
Short volume, last session
42%
Latest filing
10-Q · Nov 13
Price history
Dec 2020 to May 2026

Latest documents

2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash insufficient for 12 months, raising going-concern doubt

Reviva Pharmaceuticals Holdings, Inc. said cash and cash equivalents were approximately $17.5 million as of September 30, 2026, but current cash would not satisfy operating needs for 12 months, raising substantial doubt about its ability to continue as a going concern.

Net loss $2.3M
Read from the first part of this long document
4 source passages
Reviva Pharmaceuticals Holdings, Inc. (together with its consolidated subsidiaries, the “Company” or "Reviva") is a late-stage pharmaceutical company developing new therapies that seek to address unmet medical needs in the areas of central nervous system ("CNS"), inflammatory and cardiometabolic diseases. The Company has incurred losses since inception and as of September 30, 2026, the Company had a working capital surplus of approximately $13.1 million, an accumulated deficit of approximately $192.1 million and cash and cash equivalents on hand of approximately $17.5 million. The Company’s current cash on hand is not sufficient to satisfy its operating cash needs for the 12 months from the filing of this Quarterly Report on Form 10-Q. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the consolidated financial statements are issued. Open the document at this passage
Nov 13
Current report 8-K Events of Nov 12
Net loss $2.3 million; FDA feedback expected Q4 2026

Reviva reported a net loss of approximately $2.3 million, or $0.17 per share, for the three months ended September 30, 2026. FDA feedback on brilaroxazine is expected Q4 2026, and RECOVER-2 enrollment is targeted for 1H 2027, subject to additional financing.

Financial results, Regulation FD disclosure
4 source passages
Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the third quarter ended September 30, 2026 and summarized recent business highlights. The Company reported a net loss of approximately $2.3 million, or $0.17 per share, for the three months ended September 30, 2026, compared to a net loss of approximately $4.0 million, or $1.09 per share, for the three months ended September 30, 2025. FDA feedback on use of a new formulation of brilaroxazine in RECOVER-2 trial expected Q4 2026 Bioequivalence study on the new formulation of brilaroxazine expected to initiate in Q1 2027. Patient enrollment in the RECOVER-2 Phase 3 trial expected to initiate in 1H 2027, subject to receipt of additional financing Open the document at this passage
Nov 9
Annual report to holders ARS
One-for-twenty reverse split effective March 9, 2026

Reviva Pharmaceuticals Holdings, Inc. effected a one-for-twenty reverse stock split effective March 9, 2026, then closed a public offering on March 20, 2026 that generated approximately $8.9 million in net proceeds.

Read from the first part of this long document
4 source passages
Reviva Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) The Reverse Stock Split became effective in accordance with the terms of the amendment at 12:01 a.m. Eastern Time on March 9, 2026 under a new CUSIP number, 76152G209. On March 20, 2026, we closed a public offering (the “March 2026 Public Offering”) The net proceeds to us from the March 2026 Public Offering were approximately $8.9 million, after deducting Placement Agent fees and expenses and other offering expenses payable by us. Open the document at this passage
Nov 9
Proxy statement DEF 14A Meeting Dec 18, 2026
Stockholders to vote on reverse split and director slate

At its December 18, 2026 meeting, Reviva Pharmaceuticals Holdings, Inc. will seek five director elections and approval of a reverse split from one-for-two (1:2) to one-for-one hundred (1:100). The board could implement it by December 31, 2027 without further approval.

Read from the first part of this long document
3 source passages
This proxy statement contains information related to the Annual Meeting of Stockholders (the “Annual Meeting”) of Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “Reviva”, “we”, “us” or “our”) to be held on Friday, December 18, 2026 at 11:00 a.m. Pacific Time. To elect five director nominees to serve as directors until the next annual meeting of stockholders; To adopt and approve an amendment to the Certificate of Incorporation to effect a reverse stock split of the Company’s issued shares of common stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-one hundred (1:100), at any time prior to December 31, 2027, subject to the Board of Directors’ determination, in its sole discretion, whether or not to implement the reverse stock split and, if so, at what specific ratio within the foregoing range, without further approval or authorization of the Company’s stockholders; Open the document at this passage
Oct 29
Proxy statement PRE 14A Meeting Dec 18, 2026
Stockholders to vote on another reverse split authorization

Reviva Pharmaceuticals Holdings, Inc. asks stockholders to authorize a reverse stock split ranging from one-for-two (1:2) to one-for-one hundred (1:100) before December 31, 2027.

Read from the first part of this long document
Source passage
To adopt and approve an amendment to the Certificate of Incorporation to effect a reverse stock split of the Company’s issued shares of common stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-one hundred (1:100), at any time prior to December 31, 2027, subject to the Board of Directors’ determination, in its sole discretion, whether or not to implement the reverse stock split and, if so, at what specific ratio within the foregoing range, without further approval or authorization of the Company’s stockholders; Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$11.31M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$17.41M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+148.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −94%
below
Price vs 50-day avg −68%
below
RSI (14) 22
oversold
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −55%
trailing
6-month return −96%
trailing
YTD return −93%
this year
Relative strength −109%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $7 — 200d above 50d
Institutional flow Distributing
-80% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.12% of shares out · ▼ -4.2% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 3-yr low, contrarian setup
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 166%
annualized · 1-yr
Max drawdown −98%
past year
ATR 34.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−94% Bearish
Price vs 50-day avg
−68% Bearish
RSI (14)
22 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $7 — 200d above 50d
Institutional flow Distributing
-80% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.12% of shares out · ▼ -4.2% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $22
vs 200-day avg -94% vs 50-day avg -68%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RVPH
Reviva Pharmaceuticals Holdings, Inc.
this stock
$6.33M — — — 3.1%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1
% held
0.0%
Net QoQ
-7.7K sh
Top holder
Miller Global Investments…
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
408.8K
Days to cover
3.4d
Change
-17.7K sh
View
Short Volume
Short vol %
42%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
19
Value
$10
As of
Jul 10, 2026
View
Off-Exchange
Off-exchange %
67.8%
Week of
May 11, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-19.9M
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 13, 2026
This year
18

Reviva Pharmaceuticals Holdings, Inc. said cash and cash equivalents were approximately $17.5 million as of September 30, 2026, but current cash would not satisfy operating needs for 12 months, raising substantial doubt about its ability to continue as a going concern.

View
Exempt Offerings
Offering
Indefinite
Filed
Sep 19, 2022
View
Earnings & Events
Webcasts
Last webcast
Sep 29, 2026
View
Investor Relations
Latest news
Reviva Reports Third Quarter 2026…
Published
Nov 13, 2026
View

Performance

5D 20D 120D MTD YTD
RVPH -54.8% -55.4% -96.1% -55.2% -93.0%
SPY +2.3% +6.6% +12.9% +4.1% +9.7%
vs SPY -57.1% -62.0% -109.0% -59.3% -102.7%
Key facts CIK 1742927 CUSIP 76152G209 13F (30d) 15 filings 4 filers Visit website Investor relations